<DOC>
	<DOCNO>NCT00112346</DOCNO>
	<brief_summary>The primary purpose study estimate number patient non-small cell lung cancer whose tumor respond treatment give study .</brief_summary>
	<brief_title>Study Gemcitabine/Platinum +/- Cetuximab First-Line Treatment Patients With Advanced/Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Must advance metastatic nonsmall cell lung cancer previously treat chemotherapy . Must receive cetuximab medication target pathway cetuximab ( Iressa Tarceva ) . Must hypersensitivity severe allergic reaction monoclonal antibody must severe restrictive interstitial lung disease . Must able carry work light sedentary nature ( e.g . light house work , office work ) . It must least 4 week since last major surgery prior treatment investigational product least 12 week radiation therapy chest . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Any concurrent malignancy ( subject previous malignancy without evidence disease 5 year allow enter trial ) . Symptomatic uncontrolled metastasis central nervous system ( CNS ) . Peripheral neuropathy . Inadequate hematologic function define absolute neutrophil count ( ANC ) &lt; 1,500/mm^3 , platelet count &lt; 100,000/mm^3 , hemoglobin level &lt; 9g/dL . Inadequate liver function . Inadequate kidney function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Non-Small Lung Cancer</keyword>
</DOC>